We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Yvins Dezan
Yvins Dezan
Products
PRODUCTS
Jubilant Generics Ltd.
Yvins Dezan
and
Rajiv R. Srivastava
Price:
$117.00
View
Arx, LLC
Yvins Dezan
,
Jessica S. Estriplet
, and
Ankur C. Patel
Price:
$117.00
View
Wyeth Pharmaceutical Division of Wyeth Holdings, LLC
Kristina L. Conroy
,
Yvins Dezan
, and
Lata C. Mathew
Price:
$117.00
View
Alembic Pharmaceuticals Ltd.
Yvins Dezan
and
Kellia N. Hicks
Price:
$117.00
View
Tris Pharma, Inc.
Yvins Dezan
,
Adetutu Gidado
,
Rose L. Jean-Mary
, and
Jay B. Shah
Price:
$117.00
View
Pharmaceutics International, Inc.
Yvins Dezan
and
Junho Pak
Price:
$117.00
View
Eywa Pharma, Inc.
Yvins Dezan
and
Annet R. Rajan
Price:
$117.00
View
Progenies Pharmaceuticals, Inc.
Yvins Dezan
Price:
$117.00
View
Taejoon Pharm Co., Ltd.
Yvins Dezan
and
Philip F. Istafanos
Price:
$117.00
View
Nalco Pharma Ltd.
Yvins Dezan
Price:
$117.00
View
View All Products by Yvins Dezan
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More